Modification of myocardial substrate use as a therapy for heart failure.
about
Aberrant Lipid Metabolism Promotes Prostate Cancer: Role in Cell Survival under Hypoxia and Extracellular Vesicles BiogenesisEmerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertensionScreen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signalingApoptotic efficacy of etomoxir in human acute myeloid leukemia cells. Cooperation with arsenic trioxide and glycolytic inhibitors, and regulation by oxidative stress and protein kinase activitiesAlbiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiencyThe right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.Inhibition of sarcolemmal FAT/CD36 by sulfo-N-succinimidyl oleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia/reoxygenationLeft ventricular strain and untwist in hypertrophic cardiomyopathy: relation to exercise capacity.Hypertrophic cardiomyopathy: a heart in need of an energy bar?Anti-inflammatory and cardioprotective effects of tadalafil in diabetic miceMitochondrial approaches to protect against cardiac ischemia and reperfusion injury.Could 13C MRI assist clinical decision-making for patients with heart disease?Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat HeartAngiotensin-converting enzyme inhibition and food restriction in diabetic mice do not correct the increased sensitivity for ischemia-reperfusion injury.Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicityG-protein coupled receptor signaling in myocardium: not for the faint of heart.Excitation-contraction coupling and mitochondrial energetics.PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart.Free fatty acids as a cardiovascular risk factor.Mesenchymal stem cell transplantation for the infarcted heart: therapeutic potential for insulin resistance beyond the heart.Substrate utilization by the failing human heart by direct quantification using arterio-venous blood sampling.Potential of metabolic agents as adjunct therapies in heart failure.Cardiac metabolism and arrhythmias.Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure.Ranolazine: clinical applications and therapeutic basis.Metabolic remodeling in chronic heart failure.Fatty acid metabolism in pulmonary arterial hypertension: role in right ventricular dysfunction and hypertrophy.Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[(18)F]Fluoro-D-Glucose Uptake in Prostate Cancer Mouse Xenografts.Lipid catabolism via CPT1 as a therapeutic target for prostate cancer.Epigenetics, inflammation and metabolism in right heart failure associated with pulmonary hypertension.Early diastolic function during exertion influences exercise intolerance in patients with hypertrophic cardiomyopathy.Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle.Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension.The heart requires glycerol as an energy substrate through aquaporin 7, a glycerol facilitator.Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir.Nox4 reprograms cardiac substrate metabolism via protein O-GlcNAcylation to enhance stress adaptation.Decreased glycolytic metabolism in non-compaction cardiomyopathy by 18F-fluoro-2-deoxyglucose positron emission tomography: new insights into pathophysiological mechanisms and clinical implications
P2860
Q26744233-94147527-D486-416B-ABB2-640AAF9C7DE4Q28083183-A80D4FBB-C26E-4525-9CB5-796DBB6CAD10Q28476186-FD806A05-0377-4592-85CB-F9C776F25FB5Q28542724-2C16AE32-5A79-4327-B949-C4CC06C816A6Q28740948-D94D49F6-000F-4F50-B60A-7F5D5CB129D1Q30585014-6A408B06-020A-4BB7-9915-23A72B349D1DQ33705758-4422B743-81D5-46F3-A53B-7B9A1F8A0D04Q33882222-29DE1CFF-AF73-4DFF-9FD8-A35DCC7532B9Q34063733-2BE017C8-FCBA-4151-95D0-1B1950EE19D6Q34428464-E3360B65-5AFD-4B95-9627-4C4432B0E863Q34854255-241F0D8B-462F-4B8D-A3C1-B425CD5270BCQ35216268-AE7096AB-70D9-4BF2-9EAF-471A80348274Q35670896-62DFF716-DDED-48EF-ACB9-852C6B244BE2Q36239967-E60FCFF5-55D1-4219-8AD5-02B43CC795B2Q36359620-47A3EBD3-FB8E-4B60-81C0-7B805DDD6759Q36844422-E728349D-603A-40F1-B82A-EFBABDA5F2BAQ36893596-8744D731-A24A-42AC-AADB-BACBBF9B151FQ37189947-A64C111E-2559-491D-B3DF-2F7D2F958CF3Q37208848-844A17E2-2113-4E69-8119-0EDA72C8D8C8Q37357426-70933C3B-3457-4CF2-89EF-1E3A6D6F1347Q37383063-644FF57E-2D01-4D44-AE00-A54BF8A50FCCQ37608595-0A87E1B0-977A-4EF7-8690-852CBB439002Q37609734-EA680417-8A8A-4D0C-8AB6-D2397E31D40BQ37785792-557CE1F2-893B-4A4D-9079-E0E4221E47BBQ38075519-7653F4CA-069A-4377-8A8B-495033841137Q38125159-275865E8-5A79-4784-85B5-AFA9463882A9Q38524717-EF286C61-4319-416E-BECA-91BBF4F74D2BQ38922956-D49DA4F2-38B0-4168-9D7C-EBE772A9F310Q38966211-C723DBC5-1017-4FC1-8F2C-61C73FF4100DQ39382663-7FF6BF21-38B9-42E7-B8B9-5C6AD63D7BEBQ39698861-3C468540-6E9B-4107-8E16-28504D71ABBFQ40096264-3D7A698E-9DDE-49B6-AEDF-396E42BA5D7BQ40302879-0EE29225-4DA6-4E54-BE7B-F10259DD8CACQ42451072-24858465-751E-4AD8-9DB4-D0FA7B64F4D8Q46615265-2EB98E92-F622-4860-9D73-D28F6A9C8F10Q47230787-78D7333C-151A-4D6F-9D70-4D7A4DA84380Q58865617-88D63C55-19E9-47FD-8EB8-4728D316E94D
P2860
Modification of myocardial substrate use as a therapy for heart failure.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Modification of myocardial substrate use as a therapy for heart failure.
@ast
Modification of myocardial substrate use as a therapy for heart failure.
@en
type
label
Modification of myocardial substrate use as a therapy for heart failure.
@ast
Modification of myocardial substrate use as a therapy for heart failure.
@en
prefLabel
Modification of myocardial substrate use as a therapy for heart failure.
@ast
Modification of myocardial substrate use as a therapy for heart failure.
@en
P2093
P2860
P356
P1476
Modification of myocardial substrate use as a therapy for heart failure.
@en
P2093
Khalid Abozguia
Kieran Clarke
Michael Frenneaux
P2860
P304
P356
10.1038/NCPCARDIO0583
P577
2006-09-01T00:00:00Z